# Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

# **Listing of Claims:**

1. (Previously Presented) A compound according to formula 1, or a pharmaceutically acceptable salt thereof

$$G^{1}$$
 $R^{3}$ 
 $C$ 
 $CH_{2})_{a}$ 
 $N$ 
 $CH_{2})_{b}$ 
 $C$ 
 $CH_{2}$ 

wherein:

- G<sup>1</sup> is a group according to formula 6

- A<sup>3</sup> is selected from S, NH, N-alkyl, -CH=CH- and -CH=N-;
- A<sup>4</sup> and A<sup>5</sup> are each selected from CH and N;
- A<sup>6</sup> is selected from CH<sub>2</sub>, NH, N-alkyl and O;
- $A^7$  and  $A^{11}$  are selected from C and N;
- A<sup>8</sup> and A<sup>9</sup> are selected from CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- $A^{10}$  is selected from -CH=CH-, CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub> $R^7$  and S;
- X1 is selected from O and NH;
- R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> are each selected from H, alkyl, O-alkyl, F, Cl and Br;
- R<sup>4</sup> is selected from H, alkyl, alkenyl, alkynyl, optionally substituted phenyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyridyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted

 $CH_2-R^8$ , - $(CH_2)_g$ -CH(OH)- $(CH_2)_h$ - $R^8$ , - $(CH_2)_i$ -O- $(CH_2)_j$ - $R^8$  and  $CH_2$ - $R^8$ ;

- R<sup>7</sup> is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, NH-acyl, N(alkyl)-acyl, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;
- R<sup>8</sup> is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)-acyl, N<sub>3</sub>, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;
- a is 1 or 2, b is 1, 2 or 3; d is 1, 2 or 3; e is 1, 2, 3 or 4; and g, h, i and j are all independently 1 or 2;

## provided that:

- not more than one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;
- A<sup>7</sup> and A<sup>11</sup> are not both simultaneously N;
- neither  $A^7$  nor  $A^{11}$  is N if one of  $A^8$ ,  $A^9$  and  $A^{10}$  is NH,  $N(CH_2)_dR^7$  or S;
- if  $A^{10}$  is not -CH=CH- then one of  $A^8$ ,  $A^9$  and  $A^{10}$  is NH,  $N(CH_2)_dR^7$  or S or one of  $A^7$  and  $A^{11}$  is N;

wherein said compound is selected from the group consisting of:

- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide;
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; and
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide.
- 2. (Original) A pharmaceutical composition comprising a compound according to claim 1 as an active agent.
- 3. (Original) A pharmaceutical composition according to Claim 2 formulated as a tablet or capsule for oral administration.
- 4. (Currently Amended) A pharmaceutical composition according to Claim 2, comprising an amount of said <u>active agent</u> <u>eompound according to claim 1</u> effective for treatment of primary dysmenorrhoea.
- 5. (Currently Amended) A pharmaceutical composition according to Claim 2, comprising an amount of said <u>active agent</u> <u>eompound according to claim 1</u> effective for treatment of male erectile dysfunction.
- 6. (Currently Amended) A pharmaceutical composition according to Claim 2, comprising an amount of said <u>active agent compound according to claim 1</u> effective for treatment of a condition selected from the group consisting of pre-term labour, hypertension, Raynauld's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure.

#### Claims 7-35 (Cancelled)

36. (Previously Presented) A method for treatment of a disorder selected from the group consisting of primary dysmenorrhoea, pre-term labour, hypertension, Raynauld's disease, brain oedema, motion sickness, small cell lung cancer, depression, anxiety, hyponatremia, liver cirrhosis and congestive heart failure which comprises the administration to a person in need of such treatment of therapeutically effective amount of a compound according to formula 1, or a pharmaceutically acceptable salt thereof

wherein:

- G<sup>1</sup> is selected a group according to formula 6

$$A^{4}$$

$$A^{5}$$

$$A^{6}$$

$$A^{7}$$

$$A^{11}$$

$$A^{10}$$

$$A^{11}$$

- A<sup>3</sup> is selected from S, NH, N-alkyl, -CH=CH- and -CH=N-;
- A<sup>4</sup> and A<sup>5</sup> are each selected from CH and N;
- A<sup>6</sup> is selected from CH<sub>2</sub>, NH, N-alkyl and O;
- A<sup>7</sup> and A<sup>11</sup> are selected from C and N;
- $A^8$  and  $A^9$  are selected from CH, N, NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> and S;
- $A^{10}$  is selected from –CH=CH–, CH, N, NH, N(CH2)\_dR  $^7$  and S;
- X1 is selected from O and NH;
- $R^1$ ,  $R^2$  and  $R^3$  are each selected from H, alkyl, O-alkyl, F, Cl and Br;

 $CH_2-R^8$ , - $(CH_2)_g$ -CH(OH)- $(CH_2)_h$ - $R^8$ , - $(CH_2)_i$ -O- $(CH_2)_j$ - $R^8$  and  $CH_2$ - $R^8$ ;

- R<sup>7</sup> is selected from H, alkyl, optionally substituted phenyl, F, OH, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, NH-acyl, N(alkyl)-acyl, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>;

- R<sup>8</sup> is selected from H, alkyl, alkenyl, alkynyl, acyl, optionally substituted phenyl, optionally substituted pyridyl, optionally substituted thienyl, optionally substituted furyl, optionally substituted pyrollyl, optionally substituted pyrazolyl, optionally substituted imidazolyl, optionally substituted oxazolyl, optionally substituted isoxazolyl, optionally substituted thiazolyl, optionally substituted isothiazolyl, F, OH, hydroxyalkyl, O-alkyl, O-acyl, S-alkyl, NH<sub>2</sub>, NH-alkyl, N(alkyl)<sub>2</sub>, 1-pyrrolidinyl, 1-piperidinyl, 4-morpholinyl, NH-acyl, N(alkyl)acyl, N<sub>3</sub>, CO<sub>2</sub>H, CO<sub>2</sub>-alkyl, CONH<sub>2</sub>, CONH-alkyl, CON(alkyl)<sub>2</sub>, CN and CF<sub>3</sub>; - a is 1 or 2, b is 1, 2 or 3; d is 1, 2 or 3; e is 1, 2, 3 or 4; and g, h, i and j are all independently
- 1 or 2;

## provided that:

- not more than one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S;
- A<sup>7</sup> and A<sup>11</sup> are not both simultaneously N;
- neither  $A^7$  nor  $A^{11}$  is N if one of  $A^8$ ,  $A^9$  and  $A^{10}$  is NH,  $N(CH_2)_dR^7$  or S; and
- if A<sup>10</sup> is not -CH=CH- then one of A<sup>8</sup>, A<sup>9</sup> and A<sup>10</sup> is NH, N(CH<sub>2</sub>)<sub>d</sub>R<sup>7</sup> or S or one of A<sup>7</sup> and  $A^{11}$  is N.
- 37. (Original) The method of Claim 36, wherein at least one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is H and at least one is not H.
- 38. (Original) The method of Claim 36, wherein one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H.
  - 39. (Original) The method of Claim 36, wherein X<sup>1</sup> is NH.
  - 40. (Original) The method of Claim 36, wherein a is 1 and b is 2.

Claims 41-49 (Cancelled)

- 50. (Previously Presented) The method of Claim 36, wherein A<sup>3</sup> is S and A<sup>4</sup> and A<sup>5</sup> are both CH.
- 51. (Previously Presented) The method of Claim 36, wherein A<sup>3</sup> is -CH=CH- and A<sup>4</sup> and A<sup>5</sup> are both CH.

- 52. (Previously Presented) The method of Claim 36, wherein A<sup>3</sup> is -CH=N- and A<sup>4</sup> and A<sup>5</sup> are both CH.
- 53. (Previously Presented) The method of Claim 36, wherein  $A^3$  is -CH=CH-,  $A^4$  is CH and  $A^5$  is N.

### Claim 54 (Cancelled)

- 55. (Previously Presented) The method of Claim 36, wherein A<sup>6</sup> is NH.
- 56. (Previously Presented) The method of Claim 36, wherein  $A^8$  is NH or N-( $CH_2$ )<sub>d</sub>- $R^7$ .
  - 57. (Previously Presented) The method of Claim 36, wherein A<sup>9</sup> is N and A<sup>10</sup> is CH.
- 58. (Original) The method of Claim 36, wherein one of R<sup>1</sup>, R<sup>2</sup> and R<sup>3</sup> is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and X<sup>1</sup> is NH.
- 59. (Original) The method of Claim 36, wherein one of  $R^1$ ,  $R^2$  and  $R^3$  is selected from an alkyl group, an O-alkyl group, F, Cl and Br and the others are H and  $X^1$  is NH, a is 1 and b is 2.
- 60. (Previously Presented) The method of Claim 36, wherein A<sup>4</sup>, A<sup>5</sup> and A<sup>10</sup> are all CH, A<sup>6</sup> is NH, A<sup>7</sup> and A<sup>11</sup> are both C, A<sup>8</sup> is N-(CH<sub>2</sub>)<sub>d</sub>-R<sup>7</sup> and A<sup>9</sup> is N.
- 61. (Previously Presented) The method of Claim 36, wherein R<sup>1</sup> is an alkyl group, an O-alkyl group, F, Cl or Br, R<sup>2</sup> and R<sup>3</sup> are both H, X<sup>1</sup> is NH, a is 1, b is 2, A<sup>4</sup>, A<sup>5</sup> and A<sup>10</sup> are all CH, A<sup>6</sup> is NH, A<sup>7</sup> and A<sup>11</sup> are both C, A<sup>8</sup> is N-(CH<sub>2</sub>)<sub>d</sub>-R<sup>7</sup> and A<sup>9</sup> is N.
- 62. (Original) The method of Claim 36, wherein said compound is selected from the group consisting of:
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-(3-Methylsulfanyl-propyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide, and
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide.
- 63. (Original) A method for treatment of male erectile dysfunction which comprises the administration to a person in need of such treatment of therapeutically effective amount of a compound selected from the group consisting of:
- 4-(3,3-Dimethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(3-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclohexylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-chloro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Pentyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Hexyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- (R)-4-(2-Methyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Ethyl-butyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-(2-Methyl-but-2-enyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluoro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluoro-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-ethyl-4-(3-methyl-4,10-dihydro-3H-
- 2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,

- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclopropylmethyl-piperazine-1-carboxylic acid 2-chloro-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide,
- 4-Cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; and pharmaceutically acceptable salts of the above mentioned compounds.